MDxHealth (MDXH) Competitors

Sera Prognostics (NASDAQ:SERA) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Is SERA or MDXH more profitable?

Sera Prognostics has a net margin of 0.00% compared to MDxHealth's net margin of -49.52%. Sera Prognostics' return on equity of -51.73% beat MDxHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	N/A	-51.73%	-36.94%
MDxHealth	-49.52%	-1,077.84%	-28.82%

Do institutionals & insiders hold more shares of SERA or MDXH?

54.6% of Sera Prognostics shares are held by institutional investors. 15.8% of Sera Prognostics shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has preferable valuation and earnings, SERA or MDXH?

Sera Prognostics has higher earnings, but lower revenue than MDxHealth. Sera Prognostics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$77K	1,677.76	-$36.24M	-$0.99	-3.46
MDxHealth	$90.05M	0.76	-$43.10M	-$1.27	-1.15

Which has more volatility and risk, SERA or MDXH?

Sera Prognostics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Does the MarketBeat Community favor SERA or MDXH?

MDxHealth received 5 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 55.56% of users gave MDxHealth an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote.

Company	Underperform	Outperform
Sera Prognostics	Outperform Votes 10 38.46%	Underperform Votes 16 61.54%
MDxHealth	Outperform Votes 15 55.56%	Underperform Votes 12 44.44%

Do analysts rate SERA or MDXH?

MDxHealth has a consensus target price of $6.50, suggesting a potential upside of 346.74%. Given MDxHealth's higher possible upside, analysts clearly believe MDxHealth is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
MDxHealth	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to SERA or MDXH?

In the previous week, MDxHealth had 4 more articles in the media than Sera Prognostics. MarketBeat recorded 4 mentions for MDxHealth and 0 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.89 beat MDxHealth's score of 0.89 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Overall Sentiment
Sera Prognostics	Very Positive
MDxHealth	Positive

Summary

MDxHealth beats Sera Prognostics on 9 of the 17 factors compared between the two stocks.